How Technology is Transforming Venture Capital Portfolio Management in the Modern Era

In the fast-paced world of venture capital, staying ahead of the curve is essential for success. With the rapid advancements...

Investing in startups has always been an exciting and potentially lucrative venture. However, traditionally, this type of investment was limited...

Investing in startups has always been an exciting and potentially lucrative venture. However, traditionally, this type of investment was limited...

Investing in startups has always been an exciting and potentially lucrative venture. However, traditionally, this type of investment was limited...

Private equity deals in the alternative assets space have been making headlines in recent months, with a flurry of activity...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Deal Roundup for October 31, 2023 As we bid farewell to October,...

Private equity deals in the alternative assets (AltAssets) sector have been making headlines recently, with a flurry of activity taking...

Private equity deals are a crucial aspect of the financial world, with investors constantly on the lookout for lucrative opportunities...

Private equity deals have been a hot topic in the financial world, with investors eagerly watching for the latest developments...

Flashpoint, a leading global private equity firm, is making waves in the European direct secondaries market with its new fund...

Flashpoint, a leading private equity firm, has recently announced the launch of a new fundraising initiative aimed at targeting European...

Flashpoint, a leading private equity firm, is looking to expand its presence in the European direct secondaries market with a...

Flashpoint, a leading direct secondaries firm, is looking to expand its presence in the European market with a new $150...

Flashpoint, a leading global private equity firm, has set its sights on increasing European direct secondaries deals with a new...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Deal Roundup for October 31, 2023 As we bid farewell to October,...

Private Equity Deals in Review: AltAssets Private Equity Deal Roundup for October 31, 2023 As we bid farewell to October,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Private Equity Deals in Review: AltAssets Private Equity Roundup for October 31, 2023 As we bid farewell to October 2023,...

Arango named as managing director and head of capital formation at CRG, according to PE Hub

CRG, a leading healthcare-focused investment firm, has recently announced the appointment of Michael Arango as its new managing director and head of capital formation. This move is expected to strengthen the firm’s position in the healthcare industry and expand its reach in the global market.

Arango brings with him over 20 years of experience in the financial services industry, with a focus on healthcare and life sciences. Prior to joining CRG, he served as a managing director at Goldman Sachs, where he led the firm’s healthcare equity capital markets efforts. He has also held senior positions at other leading financial institutions, including Credit Suisse and J.P. Morgan.

In his new role at CRG, Arango will be responsible for overseeing the firm’s fundraising efforts and building relationships with institutional investors, family offices, and other key stakeholders. He will also work closely with the investment team to identify new opportunities and develop strategies for maximizing returns.

According to Charles Tate, founder and chairman of CRG, Arango’s extensive experience and deep understanding of the healthcare industry make him an ideal fit for the firm. “Michael’s track record of success in healthcare finance and his ability to build strong relationships with investors will be invaluable as we continue to grow our business,” Tate said in a statement.

CRG has been a major player in the healthcare industry for over 20 years, providing capital to companies across a range of sectors, including biotechnology, medical devices, and healthcare services. The firm has invested over $3 billion in more than 50 companies since its inception, and has a proven track record of delivering strong returns to its investors.

With Arango on board, CRG is well-positioned to continue its growth trajectory and expand its reach in the global healthcare market. His expertise in capital formation and investor relations will be critical in helping the firm raise the funds it needs to support its portfolio companies and pursue new investment opportunities.

Overall, Arango’s appointment is a positive development for CRG and the healthcare industry as a whole. As the demand for innovative healthcare solutions continues to grow, firms like CRG will play an increasingly important role in providing the capital and support needed to bring these solutions to market. With Arango at the helm, CRG is well-equipped to meet this challenge and continue its success in the years ahead.